Clinical Trial: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies

Brief Summary: The primary objective of this study is to determine if Gallium-68 labeled DOTA-TOC will result in the delineation of more lesions in patients with somatostatin receptor positive malignancies than with conventional imaging.

Detailed Summary:
Sponsor: University of California, San Francisco

Current Primary Outcome: Number of lesions visualized [ Time Frame: 24 hours from injection of DOTA-TOC ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of California, San Francisco

Dates:
Date Received: June 25, 2014
Date Started: June 2014
Date Completion:
Last Updated: May 11, 2016
Last Verified: May 2016